Investigational PD-1 inhibitors in HL and NHL and biomarkers for predictors of response and outcome.

Related Articles

Investigational PD-1 inhibitors in HL and NHL and biomarkers for predictors of response and outcome.

Expert Opin Investig Drugs. 2017 Dec 12;:

Authors: Chang A, Schlafer D, Flowers CR, Allen PB

Abstract
INTRODUCTION: Inhibitors against the PD-1/PD-L1 pathway are revolutionizing the treatment and management of malignancies. Areas covered: We summarize our current understanding of the function of PD-1, its role in immune evasion, the clinical data available that support the use of PD-1 antagonist in Hodgkin and non-Hodgkin lymphomas, and potential predictors of response. Expert opinion: We anticipate that in the next 10 years, agents that modulate the immune system such as PD-1 antagonists will be increasingly used in favor over traditional cytotoxic chemotherapeutic agents. PD-1 antagonists will be combined with future immunotherapies or used as adjuncts to cellular therapy to boost tumor-specific immune responses.

PMID: 29228840 [PubMed - as supplied by publisher]

http://ift.tt/2nVuybp